Table 1.
Antiviral effect of λ-CGN against influenza A and B viruses.
| Compound | CC50a | EC50b (S.I.c) | Units | ||
|---|---|---|---|---|---|
| PR8d | HKe | Leef | |||
| λ-CGN | > 300.0 | 0.3 ± 0.1 (> 1132) | 0.3 ± 0.0 (> 1200) | 1.4 ± 0.3 (> 214.3) | μg/ml |
| p-KG03 | > 300.0 | 0.3 ± 0.1 (> 923.1) | 0.4 ± 0.1 (> 770.2) | 0.4 ± 0.0 (> 800.0) | μg/ml |
| AMTg | > 300.0 | > 100.0 (N.D.h) | 1.4 ± 0.5 (> 71.4) | > 100.0 (N.D.) | μM |
| RBVi | > 100.0 | 15.4 ± 0.3 (> 6.5) | 11.9 ± 3.5 (> 8.4) | 14.9 ± 0.4 (> 6.7) | μM |
| OSV-Cj | > 100.0 | 0.02 ± 0.01 (> 5000) | < 0.005 (> 20,000) | 1.09 ± 0.04 (> 91.7) | μM |
aThe half-maximal cytotoxic concentration.
bThe half-maximal effective concentration.
cSelectivity index, the ratio of CC50 to EC50.
dA/Puerto Rico/8/34 (H1N1).
eA/Hong Kong/8/68 (H3N2).
fB/Lee/40.
gAmantadine hydrochloride.
hNot detected.
iRibavirin.
jOseltamivir carboxylate.